Methyldopa does not alter the disposition of digoxin. 1984

C A May, and P H Vlasses, and M L Rocci, and H H Rotmensch, and B N Swanson, and R P Tannenbaum, and R K Ferguson, and W B Abrams

To investigate whether methyldopa alters digoxin disposition, eight healthy subjects received methyldopa titrated to 250 mg t.i.d. or placebo in a double-blind, cross-over manner for 16 consecutive days, with 0.25 mg intravenous digoxin coadministered on day 5 and 0.25 mg oral digoxin on days 9 to 16. Digoxin concentrations in plasma and urine were measured by RIA. Although assay sensitivity did not allow an adequate assessment of serum AUC(0-infinity) after intravenous administration, mean digoxin AUC(0-24) was 10.2 +/- 3.5 and 10.0 +/- 1.8 ng/ml X hr with placebo and methyldopa, respectively (P greater than 0.05). Mean urinary excretion after digoxin with or without methyldopa treatment was 0.204 +/- 0.34 and 0.197 +/- 0.38 mg, respectively. The mean steady-state serum concentrations of oral digoxin (AUC(0-24)/zeta) with and without methyldopa were 0.65 +/- 0.2 and 0.62 +/- 0.3 ng/ml, respectively. These data revealed no significant differences (P greater than 0.05) for various parameters with power of greater than 0.8 to detect meaningful differences of approximately 30 per cent. Thus, methyldopa did not alter digoxin disposition in healthy subjects, and a pharmacokinetic interaction in patients is unlikely.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008750 Methyldopa An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Methyldopate,alpha-Methyldopa,Aldomet,Alphamethyldopa,Apo-Methyldopa,Dopamet,Dopegit,Dopegyt,Dopergit,Hydopa,Meldopa,Nu-Medopa,Sembrina,alpha-Methyl-L-Dopa,Apo Methyldopa,Nu Medopa,alpha Methyl L Dopa,alpha Methyldopa
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

C A May, and P H Vlasses, and M L Rocci, and H H Rotmensch, and B N Swanson, and R P Tannenbaum, and R K Ferguson, and W B Abrams
January 1998, Journal of clinical pharmacology,
C A May, and P H Vlasses, and M L Rocci, and H H Rotmensch, and B N Swanson, and R P Tannenbaum, and R K Ferguson, and W B Abrams
December 1982, British journal of clinical pharmacology,
C A May, and P H Vlasses, and M L Rocci, and H H Rotmensch, and B N Swanson, and R P Tannenbaum, and R K Ferguson, and W B Abrams
July 1985, British journal of clinical pharmacology,
C A May, and P H Vlasses, and M L Rocci, and H H Rotmensch, and B N Swanson, and R P Tannenbaum, and R K Ferguson, and W B Abrams
June 1992, Annals of neurology,
C A May, and P H Vlasses, and M L Rocci, and H H Rotmensch, and B N Swanson, and R P Tannenbaum, and R K Ferguson, and W B Abrams
August 1990, Journal of clinical pharmacology,
C A May, and P H Vlasses, and M L Rocci, and H H Rotmensch, and B N Swanson, and R P Tannenbaum, and R K Ferguson, and W B Abrams
July 1982, Clinical pharmacology and therapeutics,
C A May, and P H Vlasses, and M L Rocci, and H H Rotmensch, and B N Swanson, and R P Tannenbaum, and R K Ferguson, and W B Abrams
May 1988, The Journal of infectious diseases,
C A May, and P H Vlasses, and M L Rocci, and H H Rotmensch, and B N Swanson, and R P Tannenbaum, and R K Ferguson, and W B Abrams
August 2001, Epilepsy research,
C A May, and P H Vlasses, and M L Rocci, and H H Rotmensch, and B N Swanson, and R P Tannenbaum, and R K Ferguson, and W B Abrams
November 2000, Journal of clinical pharmacology,
C A May, and P H Vlasses, and M L Rocci, and H H Rotmensch, and B N Swanson, and R P Tannenbaum, and R K Ferguson, and W B Abrams
May 1991, Postgraduate medical journal,
Copied contents to your clipboard!